仑伐替尼联合局部疗法治疗PD-L1基因阳性门脉癌栓程氏分型Ⅰ~Ⅲ型肝癌疗效观察  

Curative Effect of Lenvatinib Combined with Locoregional Therapy on PD-L1-positive Hepatocellular Carcinoma Patients with Type Ⅰ-Ⅲ Portal Vein Tumor Thrombus According to Cheng’s Classification

作　　者：陈珑[1] 刘宇杰 田素青[2] 王翠英 何冬雷[3] CHEN Long;LIU Yujie;TIAN Suqing;WANG Cuiying;HE Donglei(Department of Oncology,Sanya Central Hospital,The Third People’s Hospital of Hainan Province,Sanya 572000,China;Department of Radiation Oncology,Peking University Third Hospital,Beijing 100191,China;Department of Gastrointestinal Cancer Surgery,The First Affiliated Hospital of Hainan Medical College,Haikou 570100,China)

机构地区：[1]三亚中心医院(海南省第三人民医院)肿瘤治疗中心,三亚572000 [2]北京大学第三医院肿瘤放疗科,北京100191 [3]海南医学院第一附属医院胃肠肿瘤外科,海口570100

出　　处：《肿瘤防治研究》2022年第1期53-57,共5页Cancer Research on Prevention and Treatment

摘　　要：目的比较仑伐替尼联合局部疗法与局部疗法治疗PD-L1基因阳性门脉癌栓程氏分型Ⅰ~Ⅲ型肝癌患者的临床疗效。方法仑伐替尼联合局部疗法组患者口服仑伐替尼12 mg每天一次(体重≥60 kg)或8 mg每天一次(体重<60 kg)。局部治疗组患者仅行局部治疗。回顾性分析两组患者临床资料和预后。结果联合组和局部治疗组CR+PR分别为78.1%和53.6%。联合组有效率和疾病控制率均高于局部疗法组(P<0.05);生存分析结果提示:联合组患者的总生存率高于局部疗法组,差异有统计学意义(P<0.05)。结论仑伐替尼联合局部疗法治疗PD-L1基因阳性门脉癌栓程氏分型Ⅰ~Ⅲ型肝癌疗效较好,患者总生存率较局部疗法高。Objective To compare curative effect between lenvatinib combined with locoregional therapy and locoregional therapy on PD-L1-positive hepatocellular carcinoma patients with type Ⅰ-Ⅲ portal vein tumor thrombus according to Cheng’s classification.Methods The patients in lenvatinib combined with locoregional therapy group received orally-administered lenvatinib at a dose of 12 mg qd for patients≥60 kg or 8 mg qd for patients<60 kg.The locoregional therapy group only received locoregional therapy.We retrospectively analyzed the clinical data and prognosis of two groups.Results The CR+PR were 78.1% and 53.6% in the combination group and locoregional therapy group,respectively (P<0.05).The response rate,disease control rate and overall survival of the combination group were higher than those in the locoregional therapy group (P<0.05).Conclusion The curative effect and overall survival of lenvatinib combined with locoregional therapy is better than locoregional therapy on PD-L1-positive hepatocellular carcinoma patients with type Ⅰ-Ⅲ portal vein tumor thrombus according to Cheng’s classification.

关 键 词：肝癌 仑伐替尼 局部治疗 门脉癌栓 PD-L1 

分 类 号：R735.7[医药卫生—肿瘤]